Dan Burrows

Dan Burrows

Dan Burrows is a veteran of CBS MoneyWatch, DailyFinance, SmartMoney and Dow Jones MarketWatch, and has written for The Wall Street Journal, Consumer Reports and other publications. He favors value investing and writes about asset prices and macroeconomic trends for the long-term investor. He holds no individual securities.

Recent Articles

Pfizer, Merck Stock – Same Ol’ Slumping Revenues, Same Mixed Prospects

The loss of exclusivity on blockbuster drugs continued to weigh in the top line at both Pfizer and Merck in the most recent quarter.

3 Dividend Stocks Juicing Returns With Buybacks

Find out how dividend stocks engaging in stock buybacks offer a double-whammy when it comes to total returns.

Dollar Tree Extends the M&A Branch to Family Dollar (DLTR, FDO)

Dollar Tree's deal for Family Dollar should get shares in all dollar stores like FDO, DG and DLTR stock moving again, especially if the competition doesn't stand pat.

CYNK Stock Crushed After Trading Halt Is Lifted

The SEC ban on trading CYNK stock was lifted Friday, and it immediately crashed and burned.

Don’t Get Burned by Under Armour Stock

Under Armour is on fire, but with a sky-high valuation, Under Armour stock is too hot to handle.

Stock Showdown: Ford vs. GM stock

The auto makers offer a range of quality vehicles in a strong sales environment, but Ford stock and GM stock are not the same investment.

PEP Stock – Is PepsiCo Right for Retirement?

Soda consumption has been in decline for years at PepsiCo, making the case for PEP stock as a retirement holding cloudy at best.

Apple’s So-So Quarter Could Kill AAPL’s Mojo

Apple earnings beat the Street by 5 cents, but other metrics missed or only matched forecasts. Will that take the pop out of AAPL stock?

3 Global Food & Beverage Giants on the Ropes

As the latest quarterly earnings showed once again, headwinds afflicting MCD, Yum and KO stock aren't going away anytime soon.

Another Headwind for Walmart – Overseas Weakness (WMT)

WMT stock is negative on the year, and there's a lot more weighing it down than just poor results in the U.S.